Last edition
News about "Ionis Pharmaceuticals"
AstraZeneca, Ionis' Wainua Misses Phase 3 Primary Endpoint in ATTR-CM Trial
AstraZeneca and Ionis reported that Wainua (eplontersen) missed the primary endpoint in the phase 3 CARDIO-TTRansform trial for ATTR-CM, while maintaining a consistent safety profile.
Ionis Pharmaceuticals | 10/07/2026 | By News Bureau | 110
Biogen Announces Topline Phase 2 Results for Diranersen in Early Alzheimer's Disease
Ionis partner Biogen announces topline phase 2 CELIA trial results for diranersen (BIIB080), showing reduced tau pathology and cognitive benefits in patients with early Alzheimer's Disease (AD).
Ionis Pharmaceuticals | 15/05/2026 | By News Bureau | 163
FDA Accepts Ionis' Zilganersen NDA for Priority Review in AxD
Ionis’ zilganersen NDA for Alexander disease has been accepted by the FDA for Priority Review, with a PDUFA target action date set for 22nd September, 2026, marking a key regulatory milestone for the potential treatment.
Ionis Pharmaceuticals | 24/03/2026 | By News Bureau | 240
Ionis Receives FDA Approval of New Drug Application for Donidalorsen
Donidalorsen is designed to reduce the production of prekallikrein (PKK), interrupting the pathway that leads to HAE attacks.
Ionis Pharmaceuticals | 06/11/2024 | By Aishwarya | 925
Ionis Pharmaceuticals plans California manufacturing site
At an expected 217,000 square feet, the site will be double the size of Ionis' current Carlsbad, California
Ionis Pharmaceuticals | 14/10/2022 | By Sudeep Soparkar | 683
ALS drug by Biogen and Ionis Pharmaceuticals fails in trials
Biogen and Ionis Pharmaceuticals were hoping to be the first to find a cure for ALS. That dream has now fizzled out with the companies calling it quits after receiving disappointing results from a phase 1 clinical trial.
Ionis Pharmaceuticals | 27/04/2022 | By Sudeep Soparkar | 751
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy